Work

Pro/Ala/Ser (PAS) peptides as an alternative to polyethylene glycol (PEG) for the surface shielding of lipid nanoparticles (LNPs) carrying therapeutic mRNA

Year: 2026
Type: article
Abstract: Lipid nanoparticles (LNPs), comprising a mixture of cationic lipids, neutral phospholipids, cholesterol and, in particular, polyethylene glycol (PEG)-conjugated lipids on their surface, have emerged as a powerful technology to encapsulate and deliver protein-encoding mRNAs as modern vaccines or for therapeutic intervention. However, the common use of PEG for surface shielding of mRNA-LNPs has raised concerns, especially in the light of a growing prevalence of anti-PEG antibodies in the healthy population. PASylation offers a biological alternative to the chemical PEG polymer, employing recombinant or synthetic (poly)peptides made of the small natural L-amino acids Pro, Ala and Ser which, in contrast to PEG, are biodegradable. PAS sequences are conformationally disordered, fully uncharged but strongly solvated and, thus, closely match the biophysical properties of PEG chains. Based on this notion, we synthesized a novel PASylated lipid, Pga-PAS 40 -ditetradecylamine (PAS-DTA), by replacing the PEG moiety in a clinically approved PEG-lipid (ALC-0159) with a 40mer PAS peptide N-terminally protected with pyroglutamate (Pga). mRNA-LNPs were formulated with this PASylated lipid, adopting a published procedure for conventional LNPs, and their properties were compared with those prepared using common PEG-lipids. To this end, we designed template DNAs for the in vitro transcription (IVT) of mRNA encoding a PASylated murine interferon alpha-11 (mIFNα11) which, when systemically applied, is effective against hepatitis B infection of transgenic mice. mRNA-LNPs formulated with PASylated or PEGylated lipids showed practically identical RNA-encapsulation efficiencies (~ 50%), hydrodynamic diameters (85–120 nm) as well as Zeta potentials (− 4 to − 13 mV). In addition, cultured HepG2 and HEK293E cells transfected with the PASylated mRNA-LNPs encoding either enhanced green fluorescent protein (eGFP) or PAS 200 -mIFNα11 showed robust expression of both recombinant proteins. Furthermore, in a side-by-side experiment with HepG2 cells transfected with mRNA-LNPs that were prepared using PAS-DTA or two different PEG-lipids, comparable or slightly higher amounts of secreted PAS 200 -mIFNα11 were detected in the culture supernatant both by western blotting and ELISA. Taken together, our in vitro data indicate that PAS-lipids offer a viable alternative to PEG-lipids for the preparation of mRNA-LNPs, without immunochemical cross-reactivity but with potentially better tolerability for the transfected target cells.
Language: English
Open Access status: gold
Estimated APC paid: $2,690
OpenAlex ID: W7204202195
FWCI:
Cites: 81
Cited by:
Related to: 9